About the Company
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKUS News
Lilly nabs another gene therapy firm, buying hearing loss player Akouos
Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic.
Twitter, Inc. v. Taamneh
Jun 29 2022 Letter from counsel for respondent Facebook, Inc. submitted pursuant to Rule 12.6 filed. Aug 15 2022 Brief of respondents Mehier Taamneh, et al. in opposition filed. Aug 30 2022 Reply of ...
Inc. Uncensored
On this week's Inc. Uncensored podcast: What it's like being on lockdown with your significant other--and co-founder. Plus, how small businesses are navigating the loan application process.
About Inc.com | Advocates For Small Business and Entrepreneurial Success
Founded in 1979 and acquired in 2005 by Mansueto Ventures LLC, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real ...
Loading the latest forecasts...